-
In vivo -jetPEI™ reagent provides versatile,
reproducible and reliable nucleic acid delivery in animals. This linear polyethylenimine reagent is ud for:
∙ gene therapy 1,2
∙ RNA Interference 3,4
∙ protein function studies 5
∙ genetic vaccination 6
In vivo -jetPEI™ is currently ud in human clinical trials
as a delivery vector for cancer gene therapy 1.
Successful in vivo delivery of DNA, siRNA and oligonucleotides
In vivo -jetPEI™ is able to deliver DNA and to mediate gene expression in various tissues. For example, the highest level of lucifera expression is detected in the lung following intravenous injection in mice (Fig. 1).
Depending on the route of administration, in vivo -jetPEI™-mediated gene expression is also obrved in the brain, liver, pancreas, spleen, kidney, heart, bladder, skin and artery.
Fig. 1. Systemic delivery using in vivo-jetPEI™. Bioluminescent imaging of lucifera expression in living Balb/C mou using a cooled camera 24 h after gene delivery. pCMVLuc (50 µg) was
complexed with in vivo -jetPEI™ in 400 µl of 5% gluco solution and injected into the tail vein. Courtesy J.L. Coll.
Specific inhibition of protein synthesis can be achieved by delivering small oligonucleotides such as siRNA, antin or ribozyme with in vivo -jetPEI™ in animal models (Fig. 2). Recently, an in vivo -jetPEI™ derivative was successfully ud as delivery
reagent for anti-cancer therapy by RNA interference 3-4
.
Fig. 2: RNA interference in the lung with in vivo -jetPEI™. pCMVLuc (40µg) was co-transfected with 10 µg of specific anti-Luc siRNA (upper) or with a control siRNA (lower). The
complexes were injected into the tail vein of nude mice. Lucifera gene expression was monitored in living mice 24 h later by
bioluminescence imaging using a cooled CCD camera.
Multiple modes of administration in many species
Numerous delivery routes of administration have been tested using in vivo -jetPEI™ (Fig. 3). Literature references are available on the Polyplus website (Product Citation Databa).
Fig. 3. Successfully delivery routes in mou.
In vivo -jetPEI™ was successfully ud to deliver nucleic acid in many species including mou, rat, guinea pig, duck, rabbit, monkey, goat, sheep, chicken, quail, hamster cow, tadpole, shrimp and fish.
血糖高的饮食
Successful in vivo delivery of DNA, siRNA and oligonucleotides Multiple modes of administration in many species No detectable inflammatory respon Reproducible results
Polyplus-transfection SA Polyplus-trans f ection Inc. PF_in vivojetPEI_vD三星e3
BIOPARC, Boulevard S. Brant
1251 Ave of the Americas, 34th
fl.
in f o@polyplus-trans 67401 Illkirch, France
New York, NY 10020, USA Phone: + 33 (0)3 90 40 61 80 Phone: + 1 508 315 9629
Fax: + 33 (0)3 90 40 61 81
燕分飞
共度美好时光No detectable inflammatory respon
Linear PEI does not induce any pro-inflammatory respon after systemic injection, especially when
compared to highly immunogenic compounds such as lipid transfection reagents or
branched PEI 7
. Additionally, linear PEI does not generate
neutralizing antibodies, permitting repeated administrations 6
.
Unique properties of in vivo -jetPEI™
In vivo -jetPEI™ condens nucleic acids into approximately 50 nm
nanoparticles 8
that are stable for veral hours. As a result of this unique protection mechanism, aggregation of blood cells following
injection is reduced compared to other reagents 9
, thereby preventing restricted diffusion within a tissue, erythrocyte aggregation and microembolia.
The nanoparticles are sufficiently small to diffu into the tissues and enter the cells by endocytosis. in vivo -jetPEI™ favors nucleic acids relea from the endosome and transfer across of the nuclear membrane.
Reproducible results
Gene delivery using in vivo -jetPEI™ is reliable and provides reproducible data experiment after experiment (Fig. 4), without any noticeable toxic side effects obrved using other methods.
Fig. 4. Systemic delivery using in vivo -jetPEI™. pCMVLuc (50 µg) was complexed with in vivo -jetPEI™ in 5% gluco and injected retro-orbitally. After 24 h, lucifera gene expression was assd in the lung (n=8). Viability of mice was 100%.
Product Cat N° Reagent Gluco solution in vivo -jetPEI™
201-10G 0.1 ml 10 ml 201-50G
0.5 ml
2 x 10 ml
0.1ml of in vivo -jetPEI™ is sufficient to perform up to 20 intravenous injections in mou (50 µg of DNA per injection).
Bulk quantities available upon request.
带剑的成语
QC reports and cGMP-in vivo -jetPEI™ are available upon request for clinical trials.
INTELLECTUAL PROPERTY
The u of polyethylenimine (PEI) or polypropylenimine (PPI) or cationic polymers similar in structure thereto for transfecting cells, as well as compositions comprising the cationic polymers and at least one nucleic acid, are the subject matter of U.S. Patent No. 6,013,240, EP Patent No. 0770140 and foreign equivalents, for which Polyplus-transfection™ is the worldwide exclusive licene.
For additional information, plea contact our technical support at
jetPEI and Polyplus-transfection are registered trademarks of Polyplus-transfection SA.
1. Ohana et al., 2004. Gene Ther Mol Bio 8:181-19
2. 2. Vernejoul et al., 2002. Cancer Rearch 62:6124-31.
3. Urbain-Klein et al., 200
4. Gene therapy 23:1-6.
猫为什么要做绝育4. Grezelinski et al., 2006. Human Gene Therapy 17:751-66.
5. Lemkine et al., 2002. Mol. Cell. Neurosci. 19:165-174.十九八七
绍兴旅游攻略6. Garzon et al., 2005. Vacine 23:1384-92.
7. Kawakani et al., 2006. J Pharmacol Exp Ther 317:1382-90. 8. Goula et al.,1998. Gene Therapy 5:712-717. 9. Kircheis et al., 2001. Gene Therapy 8:28-40.
